Clinafloxacin, AM 1091, CI-960

Class: Fluoroquinolone

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	An analogue of ciprofloxacin designed for enhanced activity against Gram positives (1). This is effective against multi drug resistant infections (2)
Institute where first reported:	Pfizer, USA
Year first mentioned:	1986
Highest developmental phase:	Phase 3
Development status:	Inactive
Reason Dropped:	Due to concerns of adverse effects, this was discontinued at registration phase. However, according to AdisInsight this may become marketed later as Pfizer are seeking compassionate designation usage as this was for a last lline defense (1)

Chemical structure(s):
Canonical SMILES:	C1CC1N2C=C(C(=O)C3=C2C(=C(C(=C3)F)N4CCC(C4)N)Cl)C(=O)O
Isomeric SMILES:	C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)Cl)N4CCC(C4)N)F)C(=O)O
InChI:	InChI=1S/C17H17ClFN3O3/c18-13-14-10(5-12(19)15(13)21-4-3-8(20)6-21)16(23)11(17(24)25)7-22(14)9-1-2-9/h5,7-9H,1-4,6,20H2,(H,24,25)
InChI Key:	QGPKADBNRMWEQR-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/60063

External links:
Guide to Pharmacology:	clinafloxacin
Citations:	http://aac.asm.org/content/45/9/2543.full http://adisinsight.springer.com/drugs/800000525